AT1-receptor blockade, but not renin inhibition, reduces aneurysm growth and cardiac failure in fibulin-4 mice

Journal of Hypertension

Volumn 34, Issue 4, 2016, Pages 654-665

  Te Riet, Luuk ^a   Van Deel, Elza D ^a   Van Thiel, Bibi S ^a   Moltzer, Els ^a   Van Vliet, Nicole ^a   Ridwan, Yanto ^a   Van Veghel, Richard ^a   Van Heijningen, Paula M ^a   Robertus, Jan Lukas ^a   Garrelds, Ingrid M ^a   Vermeij, Marcel ^a   Van Der Pluijm, Ingrid ^a   Danser, A H Jan ^a   Essers, Jeroen ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

aneurysm; cardiac dysfunction; cardiac hypertrophy; fibulin 4; renin angiotensin system

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; BRAIN NATRIURETIC PEPTIDE; FIBULIN; FIBULIN 4; LOSARTAN; PROPRANOLOL; RENIN INHIBITOR; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; FIBULIN-4; RENIN; SCLEROPROTEIN;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ARCH; AORTA ROOT; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; HEART EJECTION FRACTION; HEART FAILURE; HEMODYNAMIC STRESS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANEURYSM; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; EXTRACELLULAR MATRIX PROTEINS; HEART FAILURE; MICE; MICE, TRANSGENIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN;

EID: 84960469701     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000845     Document Type: Article

References (57)

1. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111:816-828.
2. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan-syndrome caused by a recurrent denovo missense mutation in the fibrillin gene. Nature 1991; 352:337-339.
3. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 2004; 114:172-181.
4. Horiguchi M, Inoue T, Ohbayashi T, Hirai M, Noda K, Marmorstein LY, et al. Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase. Proc Natl Acad Sci U S A 2009; 106:19029-19034.
5. Papke CL, Yanagisawa H. Fibulin-4 and fibulin-5 in elastogenesis and beyond: Insights from mouse and human studies. Matrix Biol 2014; 37:142-149.
6. Dasouki M, Markova D, Garola R, Sasaki T, Charbonneau NL, Sakai LY, et al. Compound heterozygous mutations in fibulin-4 causing neonatal lethal pulmonary artery occlusion, aortic aneurysm, arachnodactyly, and mild cutis laxa. Am J Med Genet A 2007; 143A:2635-2641.
7. Hoyer J, Kraus C, Hammersen G, Geppert JP, Rauch A. Lethal cutis laxa with contractural arachnodactyly, overgrowth and soft tissue bleeding due to a novel homozygous fibulin-4 gene mutation. Clin Genet 2009; 76:276-281.
8. Hucthagowder V, Sausgruber N, Kim KH, Angle B, Marmorstein LY, Urban Z. Fibulin-4: a novel gene for an autosomal recessive cutis laxa syndrome. Am J Hum Genet 2006; 78:1075-1080.
9. Renard M, Holm T, Veith R, Callewaert BL, Ades LC, Baspinar O, et al. Altered TGFbeta signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency. Eur J Hum Genet 2010; 18:895-901.
10. Roussin I, Sheppard MN, Rubens M, Kaddoura S, Pepper J, Mohiaddin RH. Cardiovascular complications of cutis laxa syndrome: successful diagnosis and surgical management. Circulation 2011; 124:100-102.
11. Sawyer SL, Dicke F, Kirton A, Rajapkse T, Rebeyka IM, McInnes B, et al. Longer term survival of a child with autosomal recessive cutis laxa due to a mutation in FBLN4. Am J Med Genet A 2013; 161A:1148-1153.
12. Hanada K, Vermeij M, Garinis GA, de Waard MC, Kunen MG, Myers L, et al. Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res 2007; 100:738-746.
13. Moltzer E, te Riet L, Swagemakers SMA, van Heijningen PM, Vermeij M, van Veghel R, et al. Impaired vascular contractility and aortic wall degeneration in Fibulin-4 deficient mice: Effect of angiotensin II type 1 (AT(1)) receptor blockade. Plos One 2011; 6:e23411.
14. McLaughlin PJ, Chen Q, Horiguchi M, Starcher BC, Stanton JB, Broekelmann TJ, et al. Targeted disruption of fibulin-4 abolishes elastogenesis and causes perinatal lethality in mice. Mol Cell Biol 2006; 26:1700-1709.
15. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117-121.
16. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-Associated protein. J Biol Chem 2003; 278:2750-2757.
17. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013; 34:3491-3500.
18. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol versus losartan in children and young adults with Marfans syndrome. N Engl J Med 2014; 371:2061-2071.
19. Verdonk K, Danser AHJ, van Esch JHM. Angiotensin II type 2 receptor agonists: where should they be applied?. Expert Opin Inv Drug 2012; 21:501-513.
20. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011; 332:361-365.
21. Ye Y, Qian J, Castillo AC, Perez-Polo JR, Birnbaum Y. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther 2011; 25:505-515.
22. Weng LQ, Zhang WB, Ye Y, Yin PP, Yuan J, Wang XX, et al. Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. Acta Pharmacol Sin 2014; 35:1005-1014.
23. Hawinkels LJ, Verspaget HW, van der Reijden JJ, van der Zon JM, Verheijen JH, Hommes DW, et al. Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci 2009; 100:663-670.
24. van Kerckhoven R, Saxena PR, Schoemaker RG. Restored capillary density in spared myocardium of infarcted rats improves ischemic tolerance. J Cardiovasc Pharmacol 2002; 40:370-380.
25. Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24:37-48.
26. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MADH. Renin-Angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997; 29:1240-1251.
27. van den Bos EJ, Mees BM, de Waard MC, de Crom R, Duncker DJ. A novel model of cryoinjury-induced myocardial infarction in the mouse: a comparison with coronary artery ligation. Am J Physiol Heart Circ Physiol 2005; 289:H1291-1300.
28. van Deel ED, de Boer M, Kuster DW, Boontje NM, Holemans P, Sipido KR, et al. Exercise training does not improve cardiac function in compensated or decompensated left ventricular hypertrophy induced by aortic stenosis. J Mol Cell Cardiol 2011; 50:1017-1025.
29. Kaijzel EL, van Heijningen PM, Wielopolski PA, Vermeij M, Koning GA, van Cappellen WA, et al. Multimodality imaging reveals a gradual increase in matrix metalloproteinase activity at aneurysmal lesions in live fibulin-4 mice. Circ Cardiovasc Imaging 2010; 3:567-577.
30. Seva Pessoa B, van der Lubbe N, Verdonk K, Roks AJM, Hoorn EJ, Danser AHJ. Key developments in renin-Angiotensin-Aldosterone system inhibition. Nat Rev Nephrol 2013; 9:26-36.
31. Huang JB, Yamashiro Y, Papke CL, Ikeda Y, Lin YL, Patel M, et al. Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in Fibulin-4-Deficient mice. Sci Transl Med 2013; 5:.
32. Campbell DJ, Kladis A, Duncan AM. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 1993; 22:513-522.
33. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation 2009; 120:526-532.
34. Renard M, Holm T, Veith R, Callewaert BL, Ades LC, Baspinar O, et al. Altered TGF beta signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency. Eur J Hum Genet 2010; 18:895-901.
35. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33:407-411.
36. Chung AWY, Yeung KA, Sandor GGS, Judge DP, Dietz HC, van Breemen C. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and-9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res 2007; 101:512-522.
37. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005; 23:417-426.
38. Krop M, van Veghel R, Garrelds IM, de Bruin RJA, van Gool JMG, van den Meiracker AH, et al. Cardiac renin levels are not influenced by the amount of resident mast cells. Hypertension 2009; 54:315-321.
39. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mREN-2)-27 rats. Hypertension 2008; 52:130-136.
40. van Esch JHM, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 2010; 28:2145-2155.
41. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35:985-991.
42. van Esch JHM, Gembardt F, Sterner-Kock A, Heringer-Walther S, Le T, Lassner D, et al. Cardiac phenotype and angiotensin II levels in AT1a, AT1b and AT2 receptor single, double and triple knockouts. Cardiovasc Res 2010; 86:401-409.
43. Danser AHJ, Derkx FHM, Schalekamp MADH, Hense HW, Riegger GAJ, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)-renin levels in humans. J Hypertens 1998; 16:853-862.
44. Moltzer E, Essers J, van Esch JHM, Roos-Hesselink JW, Danser AHJ. The role of the renin-Angiotensin system in thoracic aortic aneurysms: Clinical implications. Pharmacol Therapeut 2011; 131:50-60.
45. Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002; 18:1331-1339.
46. Utsunomiya H, Nakamura M, Kakudo K, Inagami T, Tamura M. Angiotensin II AT(2) receptor localization in cardiovascular tissues by its antibody developed in AT(2) gene-Deleted mice. Regul Peptides 2005; 126:155-161.
47. Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, et al. Distribution and function of cardiac angiotensin AT(1)-receptor and AT(2)-receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994; 267:H844-H852.
48. Dietz HC. Potential phenotype-genotype correlation in Marfan Syndrome: when less is more?. Circ Cardiovasc Genet 2015; 8:256-260.
49. Franken R, den Hartog AW, Radonic T, Micha D, Maugeri A, van Dijk FS, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Gene 2015; 8:383-388.
50. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996; 28:635-640.
51. van Kesteren CAM, van Heugten HAA, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ. Angiotensin II mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol 1997; 29:2147-2157.
52. Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, et al. Dimorphic effects of transforming growth factor-beta signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler Thromb Vasc Biol 2015; 35:911-917.
53. Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, et al. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 1997; 95:1201-1206.
54. Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerdt AJ, van Veghel R, et al. Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension 2012; 60:722-729.
55. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, et al. Discovery and characterization of alamandine: a novel component of the renin-Angiotensin system. Circ Res 2013; 112:1104-1111.
56. Villela D, Leonhardt J, Patel N, Joseph J, Kirsch S, Hallberg A, et al. Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci (Lond) 2015; 128:227-234.
57. Biermann D, Heilmann A, Didie M, Schlossarek S, Wahab A, Grimm M, et al. Impact of AT2 receptor deficiency on postnatal cardiovascular development. Plos One 2012; 7:e47916.